Reuters: Regulatory News: UPDATE 1-Repligen expects FDA to reject its imaging agent

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

UPDATE 1-Repligen expects FDA to reject its imaging agent Apr 26th 2012, 14:38 April 26 | Thu Apr 26, 2012 10:38am EDT April 26 (Reuters) - Repligen Corp said it expects U.S. health regulators to reject its imaging agent used in MRI scans to detect pancreatic disease, sending its shares down as much as 45 percent. Repligen, which supplies biologic products used in manufacturing drugs, said the U.S. Food and Drug Administration notified the company about its decision to cancel the scheduled advisory committee meeting on May 31. The company said it expects the FDA to reject its marketing application on June 21, requesting additional clinical trial data. Repligen's stock was down 36 percent at $4.66 on Thursday, making it the top percentage loser on the Nasdaq.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions